Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Cencora, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$223.95 |
52 Week High | US$246.75 |
52 Week Low | US$163.37 |
Beta | 0.46 |
1 Month Change | -8.89% |
3 Month Change | -4.70% |
1 Year Change | 33.31% |
3 Year Change | 85.30% |
5 Year Change | 189.08% |
Change since IPO | 7,483.49% |
Recent News & Updates
Recent updates
Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings
Apr 05Cencora Remains Chronically Undervalued, With Material Growth Potential
Mar 25Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 18Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly
Feb 25Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 07Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price
Jan 05Cencora: Continued Economic Value On The Table Across All Investment Horizons
Jan 04A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)
Dec 15Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year
Nov 05Is Cencora (NYSE:COR) A Risky Investment?
Nov 03Cencora: New Name, Same Old Economic Leverage, Reiterate Buy
Oct 18AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate
Aug 01AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)
Jul 28We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt
Jun 19Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?
May 01Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching
Apr 10AmerisourceBergen (NYSE:ABC) Has A Pretty Healthy Balance Sheet
Mar 02AmerisourceBergen declares $0.485 dividend
Feb 01AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 25% Below Their Intrinsic Value Estimate
Jan 28AmerisourceBergen partners with pharmaceutical company Civica
Jan 23AmerisourceBergen: What Does The Valuation Look Like After The Recent Price Rise?
Jan 13Does AmerisourceBergen (NYSE:ABC) Deserve A Spot On Your Watchlist?
Jan 10AmerisourceBergen sued by DoJ over suspicious opioid orders
Dec 29Walgreens Boots Alliance sells $1.0B in AmerisourceBergen shares; $200M buyback from WBA
Dec 09AmerisourceBergen's (NYSE:ABC) Upcoming Dividend Will Be Larger Than Last Year's
Nov 08Shareholder Returns
COR | US Healthcare | US Market | |
---|---|---|---|
7D | -7.0% | -2.3% | 0.7% |
1Y | 33.3% | -0.01% | 23.9% |
Return vs Industry: COR exceeded the US Healthcare industry which returned 2.1% over the past year.
Return vs Market: COR exceeded the US Market which returned 24.2% over the past year.
Price Volatility
COR volatility | |
---|---|
COR Average Weekly Movement | 2.1% |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COR has not had significant price volatility in the past 3 months.
Volatility Over Time: COR's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 44,000 | Steve Collis | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
COR fundamental statistics | |
---|---|
Market cap | US$44.82b |
Earnings (TTM) | US$1.85b |
Revenue (TTM) | US$276.54b |
24.1x
P/E Ratio0.2x
P/S RatioIs COR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COR income statement (TTM) | |
---|---|
Revenue | US$276.54b |
Cost of Revenue | US$267.14b |
Gross Profit | US$9.40b |
Other Expenses | US$7.55b |
Earnings | US$1.85b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 9.29 |
Gross Margin | 3.40% |
Net Profit Margin | 0.67% |
Debt/Equity Ratio | 427.8% |
How did COR perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield22%
Payout RatioDoes COR pay a reliable dividends?
See COR dividend history and benchmarksCencora dividend dates | |
---|---|
Ex Dividend Date | May 09 2024 |
Dividend Pay Date | May 24 2024 |
Days until Ex dividend | 4 days |
Days until Dividend pay date | 19 days |
Does COR pay a reliable dividends?
See COR dividend history and benchmarks